Centessa Pharmaceuticals plc
CNTA
$11.80
-$1.26-9.65%
Weiss Ratings | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Rating | ||||
Reward Index | Very Weak | |||
Risk Index | Weak | |||
Risk Grade | D | |||
Reward Grade | E | |||
Rating Factors | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Dividend Index | -- | |||
Growth Index | Very Weak | |||
Efficiency Index | Very Weak | |||
Solvency Index | Excellent | |||
Total Return Index | Fair | |||
Volatility Index | Weak | |||
Beta / Standard Deviation | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Beta | 1.34 | |||
Price History | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
7-Day Total Return | -18.84% | |||
30-Day Total Return | -29.04% | |||
60-Day Total Return | -31.87% | |||
90-Day Total Return | -35.13% | |||
Year to Date Total Return | -32.57% | |||
1-Year Total Return | 13.79% | |||
2-Year Total Return | 212.17% | |||
3-Year Total Return | 19.80% | |||
5-Year Total Return | -- | |||
52-Week High % Change | -31.59% | |||
52-Week Low % Change | 68.52% | |||
Price | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
52-Week High Price | $19.09 | |||
52-Week Low Price | $7.75 | |||
52-Week Low Price (Date) | May 29, 2024 | |||
52-Week High Price (Date) | Feb 07, 2025 | |||
Valuation | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Market Cap | 1.74B | |||
Enterprise Value | 1.38B | |||
Price/Earnings (TTM) | -- | |||
Earnings Per Share (TTM) | -1.99 | |||
Earnings Per Share Growth | 26.63% | |||
Price/Earnings To Growth | -- | |||
Price/Sales (TTM) | -- | |||
Price/Book (Q) | 4.31 | |||
Enterprise Value/Revenue (TTM) | -- | |||
Price | $11.80 | |||
Enterprise Value/EBITDA (TTM) | -6.85 | |||
Enterprise Value/EBIT | -6.84 | |||
Market Cap Category | Small Cap | |||
Dividends and Shares | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Shares Outstanding | 132.05M | |||
Dividend Yield | -- | |||
Div. Per Share (Most Recent) | -- | |||
Dividend Per Share (TTM) | -- | |||
Payout Ratio (TTM) | -- | |||
Dividend Per Share (Most Recent) | -- | |||
Company Info | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Phone Number | -- | |||
Address | -- | |||
Website | www.centessa.com | |||
Country | United Kingdom | |||
Year Founded | 2020 | |||
Profitability | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Operating Margin (TTM) | -- | |||
Profit Margin | -- | |||
Management Effectiveness | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Return on Assets | -26.82% | |||
Return on Equity | -- | |||
Income Statement | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Revenue (TTM) | -- | |||
Total Revenue (TTM) | -- | |||
Revenue Per Share | -- | |||
Gross Profit (TTM) | -- | |||
EBITDA (TTM) | -200.71M | |||
EBIT (TTM) | -201.06M | |||
Net Income (TTM) | -235.76M | |||
Net Income Avl. to Common (TTM) | -235.76M | |||
Total Revenue Growth (Q YOY) | -- | |||
Earnings Growth (Q YOY) | -202.22% | |||
EPS Diluted (TTM) | -1.99 | |||
EPS Diluted Growth (Q YOY) | -124.11% | |||
Balance Sheet | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash and Short-Term Inv. (Q) | 482.18M | |||
Cash Per Share (Q) | $3.65 | |||
Total Current Assets (Q) | 536.41M | |||
Total Preferred Equity (Q) | -- | |||
Total Equity (Q) | 401.55M | |||
Current Ratio (Q) | 9.249 | |||
Book Value Per Share (Q) | $3.03 | |||
Total Assets (Q) | 576.80M | |||
Total Current Liabilities (Q) | 58.00M | |||
Total Debt (Q) | 117.83M | |||
Total Liabilities (Q) | 175.25M | |||
Total Common Equity (Q) | 401.55M | |||
Cash Flow | CNTA - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
Cash from Investing (TTM) | 31.27M | |||
Cash from Financing (TTM) | 364.75M | |||
Net Change in Cash (TTM) | 255.19M | |||
Levered Free Cash Flow (TTM) | -74.68M | |||
Cash from Operations (TTM) | -142.06M | |||